Company profile: Xintela
1.1 - Company Overview
Company description
- Provider of regenerative medicine and cancer therapies, including XSTEM, a stem cell product selected via integrin α10β1 for treating diseases such as knee osteoarthritis and venous leg ulcers; EQSTEM, a stem cell therapy for horses targeting osteoarthritis and degenerative joint diseases; and therapeutic antibodies against integrin α10β1 for certain cancers, including triple-negative breast cancer and glioblastoma.
Products and services
- XSTEM: Integrin α10β1–guided stem cell product that selects and ensures quality cells to treat various human diseases, including knee osteoarthritis and hard-to-heal venous leg ulcers
- Cancer Therapy: Integrin-targeted therapeutic antibodies that bind α10β1 expressed on certain cancer cells, addressing triple-negative breast cancer and glioblastoma through targeted antibody products
- EQSTEM: Marker-based equine stem cell product developed to treat osteoarthritis and other degenerative joint diseases in horses, leveraging Xintela’s marker technology for targeted selection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Xintela
Outpace Bio
HQ: United States
Website
- Description: Provider of innovative cell therapies designed to enhance cancer treatment efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Outpace Bio company profile →
ImmunityBio
HQ: United States
Website
- Description: Provider of clinical-stage immunotherapy solutions focused on harnessing the immune system to treat disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmunityBio company profile →
Creative Medical Technology
HQ: United States
Website
- Description: Provider of regenerative and cell therapy platforms in immunology, urology, neurology, and orthopedics, including ImmCelzTM autologous immune cell therapy; Enhanced Allogenic Platform using perinatal tissue cells; Supercharged Autologous Immunotherapy; Reprogrammed Cell Therapy with iPSCs; Rapid Autologous Therapies, and CaverStem for erectile dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Creative Medical Technology company profile →
Organogenesis
HQ: United States
Website
- Description: Provider of regenerative medicine products, including PuraPly MZ, a micronized wound matrix made from purified porcine collagen to support healing in complex surgical wounds by inhibiting excess MMPs, and PuraForce, a purified collagen matrix used for tendon reinforcement during tendon repair surgeries, providing biomechanical strength and support without bulk.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Organogenesis company profile →
Immatics
HQ: Germany
Website
- Description: Provider of TCR-based cancer immunotherapies and discovery platforms, including ACTengine personalized TCR cell therapy, ACTallo off-the-shelf gamma delta T-cell therapies with TCRs or CARs, TCER bispecific T-cell engaging receptors, and the XPRESIDENT, XCEPTOR, and XCUBE platforms for target identification, TCR discovery/engineering, and AI-powered immunoinformatics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immatics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Xintela
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Xintela
2.2 - Growth funds investing in similar companies to Xintela
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Xintela
4.2 - Public trading comparable groups for Xintela
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →